Global Pruritus Therapeutics Market Overview

The global Pruritus Therapeutics Market was estimated at USD 12.11 billion in 2021 and is projected to reach USD 16.37 billion by 2028, growing at a CAGR of 4.4% over the analysis period.

Itchy skin is an uncomfortable, annoying sensation that causes individuals to scratch. Dry skin is a common cause of itchy skin, also known as pruritus. It's more frequent in older people since their skin dries out with age. The skin may appear normal, red, rough, or bumpy depending on the reason for the itching. Scratching repeatedly can result in raised, thickened skin that might bleed or become infected. Many people find relief from self-care methods such as frequent moisturizing, gentle cleansers, and lukewarm baths. Long-term relief requires determining and treating the source of itchy skin. Pruritus can also be caused by medical conditions such as kidney failure, liver disease, thyroid disease, cancer, and diabetes. Antibiotics, antifungals, anticonvulsants, and a few natural remedies such as topical application of coconut oil, vitamin E, and honey are utilized to treat pruritus. The increase in the number of individuals suffering from chronic disorders, and the rising geriatric population are the two prominent factors expected to drive the development of the pruritus therapeutics market over the forecasted period.

Market Dynamics And Factors For Pruritus Therapeutics Market

Drivers:

An increasing number of individuals suffering from dermatitis and allergic diseases

Dermatitis is a general term for conditions that cause inflammation of the skin. It includes atopic dermatitis (eczema), contact dermatitis, and seborrheic dermatitis (dandruff). These conditions cause red rashes, dry skin, and itchiness among other symptoms. Atopic dermatitis (AD) is one of the most frequent inflammatory skin diseases in humans, affecting up to 20% of children living in higher-income countries. The first signs of the disease usually develop between the 3rd and 6th months of life, and about 60% of cases occur within the first two years of life; 80% of affected children experience symptoms before the 6th year of life. AD is more common in adults than previously thought, with up to nearly 10% affected. These cases result from persistent or recurrent childhood AD or the new onset of AD later in life. Up to 30% of pediatric and 50% of adult AD patients suffer from moderate to severe forms of the disease. Overall, AD incidence is increasing worldwide, indicating that an environmental factor is contributing to the development of the disease. In addition, the growing geriatric population is also contributing to the increasing cases of dermatitis thereby, driving the growth of the pruritus therapeutics market during the studied period.

People with medical disorders, including diabetes, HIV infection/AIDS, and various types of cancer

Diabetes can be associated with pruritus, more often localized than generalized. It mainly affects the scalp, ankles, feet, trunk, or genitalia. Pruritus is more likely in patients with diabetes who have dry skin or diabetic neuropathy. These are complications of diabetes that develop when high blood glucose levels cause damage to nerve fibers, particularly those in the feet and hands. According to a study by PubMed, approximately 50 % of patients with diabetes will develop neuropathy in their lifetime. The IDF study estimated that there were 537 million individuals living with diabetes in 2021, and this number is poised to reach 643 million by 2030. This rise in the diabetic population is anticipated to increase the number of individuals suffering from pruritus thereby, supporting the development of the market in the projected period.

Restraints:

High treatment cost as advanced biologics are administered

Dermatological treatments have gained tremendous importance in recent years. Skin plays an important part in everyone's life as it can affect psychological and social behavior. Technology has introduced innovative solutions in the market for the treatment of several skin diseases however, it has also increased the treatment cost. Incremental costs linked with pruritus have remained study steady over the years, but expenditures resulting from the condition are shifting from outpatient and inpatient settings to the emergency department and home health services. An article published in the Journal of the American Academy of Dermatology examined pruritus-related healthcare expenditures in the United States from 2007 to 2015, using data from the Medical Expenditure Panel Survey. According to the findings, pruritus can eventually become a significant burden on both medical and financial health. Even after controlling for sociodemographic factors and comorbidities, patients with pruritus are estimated to incur USD 4,843.68 more in annual healthcare costs than those without pruritus. Thereby, the high cost associated with the treatment of pruritus is anticipated to hamper the growth of the market in the forecasted period.

Opportunities:

Development of innovative solutions for treating the pruritic condition

The increasing prevalence of pruritus among individuals has stimulated market players to develop innovative solutions for the treatment of the disease. This has resulted in partnerships among key players for the development and production of advanced drugs. For instance, in April 2022, Almirall S.A. announced a research collaboration with the University of Dundee to develop a novel approach against chronic and debilitating dermatological diseases characterized by itch, or pruritus. The collaboration will build on Dr. John Foerster's team at the University of Dundee's proprietary immune-based treatment for chronic inflammatory conditions. Furthermore, some of the key players have raised funding to boost the development of novel drugs. For instance, in September 2020, Escient Pharmaceuticals Inc. announced the completion of a $77.5 million Series B financing as well as the start of a Phase 1/1b clinical trial for EP547, an MRGPRX4-targeted product candidate for the treatment of cholestatic and uremic pruritus. EP547 was discovered and is being developed by Escient based on the discovery of disease-related accumulation of key metabolites that specifically activate the MRGPRX4 itch receptor, and the proceeds will be used to support clinical development. Thereby, funding and collaborations for the development of innovative treatment solutions are expected to create lucrative opportunities for market players over the analysis period.

Supportive government regulations

Pharmaceutical and biotech companies are highly regulated as they manufacture lifesaving drugs. There are various regulations and the most prominent are the European Commission, and the FDA. Drugs passed by these commissions are considered most safe for therapeutics. For instance, in April 2022, Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Cara Therapeutics announced that the European Commission (EC) approved Kapruvia (difelikefalin) for the treatment of moderate-to-severe pruritis associated with chronic kidney disease (CKD) in adult hemodialysis patients. Under the brand name Korsuva, the treatment was approved by the FDA in the United States in August 2021 for the same indication. The European Commission's approval allows the treatment to be used in all European Union member countries, as well as Iceland, Liechtenstein, and Norway. Kapruvia is the first approved therapy in Europe for the treatment of pruritis associated with CKD in hemodialysis patients, according to the company. The company is expecting to launch its first batch in Europe in the second half of 2022. Thus, the supportive government regulations are expected to create profitable opportunities for market players over the projected timeframe.

Segmentation Analysis Of Pruritus Therapeutics Market

By Drug Class, the corticosteroids segment is anticipated to lead the growth of the pruritus therapeutics market over the projected period. Over the last 40 years, topical corticosteroids have been the mainstay of atopic dermatitis treatment. Hydrocortisone was the first corticosteroid to be used; today 30 additional corticosteroid compounds are approved for the treatment of atopic dermatitis. Several studies have been published that demonstrate the efficacy of corticosteroids. Moreover, topical corticosteroids along with other drugs can significantly alleviate pruritic conditions. For instance, in December 2021, Eli Lilly and Company announced that Lebrikizumab, an IL-13 inhibitor, significantly enhanced disease seriousness when coupled with topical corticosteroids (TCS) in people with moderate-to-severe atopic dermatitis. Similarly, several drugs are being developed for effective treatment of the disease thereby, strengthening the expansion of the corticosteroid segment over the projected period.

By Disease Type, the atopic dermatitis segment is expected to have the highest share of the pruritus therapeutics market in the forecasted period. Atopic Dermatitis (AD), also known as eczema, is a common inflammatory skin condition. Patients with AD frequently experience itchy skin, red and brown blotches, swollen or dry patches, and anxiety as a result of the condition. It also increases the skin's sensitivity to environmental irritants and allergens. Eczema affects 31.6 million people (10.1%) in the United States, with prevalence peaking during childhood. Eczema affects one out of every ten people at some point in their lives, with prevalence peaking in childhood. Thus, the increase in the number of individuals suffering from eczema is anticipated to support the growth of the segment during the projected period.

By Route Of Administration, the topical segment is expected to have the highest share of the pruritus therapeutics market in the analysis period. In recent years, there has been a significant increase in the use of topical medications. This is largely because the medication has been shown to have more benefits than drawbacks. After all, the skin is an ideal site for drug administration because it has both systemic and local effects. There has been a rise in the number of products for topical administration as these are easy to administer, and patients can administer these at homecare. The growing inclination toward topical drugs coupled with advanced topical solutions is the major factor anticipated to support the growth of the segment over the projected period.

Regional Analysis Of Pruritus Therapeutics Market

The North American region is anticipated to dominate the pruritus therapeutics market over the forecasted period attributed to the growing prevalence of chronic diseases such as diabetes, eczema, and other skin-related disorders. According to the National Eczema Association, 31.6 million Americans (10.1%) have some form of eczema, with prevalence peaking during childhood. It is also estimated that one in every ten people will develop eczema during their lifetime, with prevalence peaking in childhood. Furthermore, 9.6 million children under the age of 18 in the United States have AD, with one-third suffering from moderate to severe disease. An estimated 16.5 million adults in the United States (7.3%) have AD, with nearly 40% suffering from moderate to severe disease. In addition, 51 million adults in this region are living with diabetes (IDF 2021). This number is expected to reach 57 million by 2030 thus, supporting the development of the pruritus therapeutics market over the projected period.

The European region is forecasted to have the second highest share of the pruritus therapeutics market in the studied period. The presence of prominent market players, research institutes, and the increasing prevalence of chronic skin diseases are the major factors stimulating the development of the market in this region. Moreover, due to the rise in agreements and sales partnerships among market players, the pruritus therapeutics market in Europe may witness lucrative growth during the studied period. For instance, on February 17, 2021, Almirall S.A., a global biopharmaceutical company, and MC2 Therapeutics, a commercial-stage pharmaceutical company that develops topical therapies for autoimmune and chronic inflammatory conditions, have confirmed that MC2 Therapeutics has granted Almirall exclusive European rights to commercialize WYNZORA Cream for the treatment of plaque psoriasis, which is a common cause of psoriasis itching (pruritus) in adults. These factors are expected to stimulate the growth of the pruritus therapeutics market in the forecasted period.

The pruritus therapeutics market in the Asia-Pacific region is anticipated to develop at the highest CAGR over the projected period. India, China, Japan, South Korea, Thailand, and Singapore are the prominent countries driving the development of the market in this region. According to Unilever R&D and NIBMG-academia-industry, one in every five children in India suffers from eczema, also known as atopic dermatitis. Since 1997, there has been a significant increase in the number of people suffering from AD. Furthermore, epidemiological evidence suggested that AD affects 20% of children and 11% of adults in Singapore. The growing diabetic population in this region is also a major factor stimulating the growth of the market. According to IDF, in 2021, 90 million individuals in South East Asia are diabetic. This number is estimated to reach 113 million by 2030 thus, supporting the development of the pruritus therapeutics market over the projected period.

COVID-19 Impact on Pruritus Therapeutics Market

The effect of COVID-19 on the Atopic Dermatitis (AD) population is still unclear. The rapid spread of the COVID-19 pandemic impacted negatively many aspects of daily life. In terms of disease prevention, preventive measures such as social distancing and hand hygiene habits, as well as patient education, were of the greatest priority. The extreme, ongoing stress involved with coping with a chronic skin problem, along with the risk of contracting COVID-19, adds to patients' worry. Although SARS-CoV-2 is mostly responsible for respiratory problems rather than skin diseases, it has a significant impact on dermatology and dermatological patients. Stress, harmful compounds, and allergens contained in disinfectants and cleansers may exacerbate a variety of chronic skin diseases. During this extraordinary time, the dermatology community faced unprecedented challenges in improving the mental health and quality of life of individuals with chronic diseases such as AD. During the COVID-19 pandemic, atopic dermatitis was associated with a lower overall health rating, lower life satisfaction, and lower quality of life relating to mental health. With the growing vaccination rate coupled with declining cases of infected individuals, the demand for pruritus therapeutics is anticipated to increase in the forecasted period.

Top Key Players Covered In Pruritus Therapeutics Market

• AbbVie Inc.
• Sanofi SA
• Galderma Laboratories LP
• EPI Health LLC
• Cara Therapeutics
• Actavis
• Trevi Therapeutics
• Novartis AG
• Pfizer Inc.
• Merck & Co. Inc.
• Sun Pharmaceuticalc
• GlaxoSmithKlinePLC
• Glenmark Pharmaceuticals Ltd.
• Abbott Laboratories, and Other Major Players.

Key Industry Development In Pruritus Therapeutics Market

In January 2022, AbbVie announced that RINVOQ® (upadacitinib) has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of moderate to severe atopic dermatitis in adults and children 12 years of age and older whose disease has not responded in comparison to past treatment and is not adequately regulated with other medications or injections.

In January 2022, Galderma announced the acquisition of ALASTIN Skincare, after it received antitrust clearance from U.S. authorities. The patented TriHex Technology®, a proprietary blend of peptides and active botanicals to support the appearance of regenerated skin, supports ALASTIN's product offerings. This acquisition will bolster the position of Galderma in the pruritus therapeutics market.

Chapter 1: Introduction
 1.1 Research Objectives
 1.2 Research Methodology
 1.3 Research Process
 1.4 Scope and Coverage
  1.4.1 Market Definition
  1.4.2 Key Questions Answered
 1.5 Market Segmentation

Chapter 2:Executive Summary

Chapter 3:Growth Opportunities By Segment
 3.1 By Drug Class
 3.2 By Disease Type
 3.3 By Route Of Administration

Chapter 4: Market Landscape
 4.1 Porter's Five Forces Analysis
  4.1.1 Bargaining Power of Supplier
  4.1.2 Threat of New Entrants
  4.1.3 Threat of Substitutes
  4.1.4 Competitive Rivalry
  4.1.5 Bargaining Power Among Buyers
 4.2 Industry Value Chain Analysis
 4.3 Market Dynamics
  4.3.1 Drivers
  4.3.2 Restraints
  4.3.3 Opportunities
  4.5.4 Challenges
 4.4 Pestle Analysis
 4.5 Technological Roadmap
 4.6 Regulatory Landscape
 4.7 SWOT Analysis
 4.8 Price Trend Analysis
 4.9 Patent Analysis
 4.10 Analysis of the Impact of Covid-19
  4.10.1 Impact on the Overall Market
  4.10.2 Impact on the Supply Chain
  4.10.3 Impact on the Key Manufacturers
  4.10.4 Impact on the Pricing

Chapter 5: Pruritus Therapeutics Market by Drug Class
 5.1 Pruritus Therapeutics Market Overview Snapshot and Growth Engine
 5.2 Pruritus Therapeutics Market Overview
 5.3 Calcineurin Inhibitors
  5.3.1 Introduction and Market Overview
  5.3.2 Historic and Forecasted Market Size (2016-2028F)
  5.3.3 Key Market Trends, Growth Factors and Opportunities
  5.3.4 Calcineurin Inhibitors: Grographic Segmentation
 5.4 Corticosteroids
  5.4.1 Introduction and Market Overview
  5.4.2 Historic and Forecasted Market Size (2016-2028F)
  5.4.3 Key Market Trends, Growth Factors and Opportunities
  5.4.4 Corticosteroids: Grographic Segmentation
 5.5 Counterirritants
  5.5.1 Introduction and Market Overview
  5.5.2 Historic and Forecasted Market Size (2016-2028F)
  5.5.3 Key Market Trends, Growth Factors and Opportunities
  5.5.4 Counterirritants: Grographic Segmentation
 5.6 Immunosuppressant
  5.6.1 Introduction and Market Overview
  5.6.2 Historic and Forecasted Market Size (2016-2028F)
  5.6.3 Key Market Trends, Growth Factors and Opportunities
  5.6.4 Immunosuppressant: Grographic Segmentation
 5.7 Antihistamines
  5.7.1 Introduction and Market Overview
  5.7.2 Historic and Forecasted Market Size (2016-2028F)
  5.7.3 Key Market Trends, Growth Factors and Opportunities
  5.7.4 Antihistamines: Grographic Segmentation
 5.8 Others
  5.8.1 Introduction and Market Overview
  5.8.2 Historic and Forecasted Market Size (2016-2028F)
  5.8.3 Key Market Trends, Growth Factors and Opportunities
  5.8.4 Others: Grographic Segmentation

Chapter 6: Pruritus Therapeutics Market by Disease Type
 6.1 Pruritus Therapeutics Market Overview Snapshot and Growth Engine
 6.2 Pruritus Therapeutics Market Overview
 6.3 Allergic Contact Dermatitis
  6.3.1 Introduction and Market Overview
  6.3.2 Historic and Forecasted Market Size (2016-2028F)
  6.3.3 Key Market Trends, Growth Factors and Opportunities
  6.3.4 Allergic Contact Dermatitis: Grographic Segmentation
 6.4 Atopic Dermatitis
  6.4.1 Introduction and Market Overview
  6.4.2 Historic and Forecasted Market Size (2016-2028F)
  6.4.3 Key Market Trends, Growth Factors and Opportunities
  6.4.4 Atopic Dermatitis: Grographic Segmentation
 6.5 Psoriasis
  6.5.1 Introduction and Market Overview
  6.5.2 Historic and Forecasted Market Size (2016-2028F)
  6.5.3 Key Market Trends, Growth Factors and Opportunities
  6.5.4 Psoriasis: Grographic Segmentation
 6.6 Urticaria
  6.6.1 Introduction and Market Overview
  6.6.2 Historic and Forecasted Market Size (2016-2028F)
  6.6.3 Key Market Trends, Growth Factors and Opportunities
  6.6.4 Urticaria: Grographic Segmentation
 6.7 Others
  6.7.1 Introduction and Market Overview
  6.7.2 Historic and Forecasted Market Size (2016-2028F)
  6.7.3 Key Market Trends, Growth Factors and Opportunities
  6.7.4 Others: Grographic Segmentation

Chapter 7: Pruritus Therapeutics Market by Route Of Administration
 7.1 Pruritus Therapeutics Market Overview Snapshot and Growth Engine
 7.2 Pruritus Therapeutics Market Overview
 7.3 Oral
  7.3.1 Introduction and Market Overview
  7.3.2 Historic and Forecasted Market Size (2016-2028F)
  7.3.3 Key Market Trends, Growth Factors and Opportunities
  7.3.4 Oral: Grographic Segmentation
 7.4 Parenteral
  7.4.1 Introduction and Market Overview
  7.4.2 Historic and Forecasted Market Size (2016-2028F)
  7.4.3 Key Market Trends, Growth Factors and Opportunities
  7.4.4 Parenteral: Grographic Segmentation
 7.5 Topical
  7.5.1 Introduction and Market Overview
  7.5.2 Historic and Forecasted Market Size (2016-2028F)
  7.5.3 Key Market Trends, Growth Factors and Opportunities
  7.5.4 Topical: Grographic Segmentation

Chapter 8: Company Profiles and Competitive Analysis
 8.1 Competitive Landscape
  8.1.1 Competitive Positioning
  8.1.2 Pruritus Therapeutics Sales and Market Share By Players
  8.1.3 Industry BCG Matrix
  8.1.4 Ansoff Matrix
  8.1.5 Pruritus Therapeutics Industry Concentration Ratio (CR5 and HHI)
  8.1.6 Top 5 Pruritus Therapeutics Players Market Share
  8.1.7 Mergers and Acquisitions
  8.1.8 Business Strategies By Top Players
 8.2 ABBVIE INC.
  8.2.1 Company Overview
  8.2.2 Key Executives
  8.2.3 Company Snapshot
  8.2.4 Operating Business Segments
  8.2.5 Product Portfolio
  8.2.6 Business Performance
  8.2.7 Key Strategic Moves and Recent Developments
  8.2.8 SWOT Analysis
 8.3 SANOFI SA
 8.4 GALDERMA LABORATORIES LP
 8.5 EPI HEALTH LLC
 8.6 CARA THERAPEUTICS
 8.7 ACTAVIS
 8.8 TREVI THERAPEUTICS
 8.9 NOVARTIS AG
 8.10 PFIZER INC.
 8.11 MERCK & CO INC.
 8.12 SUN PHARMACEUTICAL
 8.13 GLAXOSMITHKLINE PLC
 8.14 GLENMARK PHARMACEUTICALS LTD.
 8.15 ABBOTT LABORATORIES
 8.16 OTHER MAJOR PLAYERS

Chapter 9: Global Pruritus Therapeutics Market Analysis, Insights and Forecast, 2016-2028
 9.1 Market Overview
 9.2 Historic and Forecasted Market Size By Drug Class
  9.2.1 Calcineurin Inhibitors
  9.2.2 Corticosteroids
  9.2.3 Counterirritants
  9.2.4 Immunosuppressant
  9.2.5 Antihistamines
  9.2.6 Others
 9.3 Historic and Forecasted Market Size By Disease Type
  9.3.1 Allergic Contact Dermatitis
  9.3.2 Atopic Dermatitis
  9.3.3 Psoriasis
  9.3.4 Urticaria
  9.3.5 Others
 9.4 Historic and Forecasted Market Size By Route Of Administration
  9.4.1 Oral
  9.4.2 Parenteral
  9.4.3 Topical

Chapter 10: North America Pruritus Therapeutics Market Analysis, Insights and Forecast, 2016-2028
 10.1 Key Market Trends, Growth Factors and Opportunities
 10.2 Impact of Covid-19
 10.3 Key Players
 10.4 Key Market Trends, Growth Factors and Opportunities
 10.4 Historic and Forecasted Market Size By Drug Class
  10.4.1 Calcineurin Inhibitors
  10.4.2 Corticosteroids
  10.4.3 Counterirritants
  10.4.4 Immunosuppressant
  10.4.5 Antihistamines
  10.4.6 Others
 10.5 Historic and Forecasted Market Size By Disease Type
  10.5.1 Allergic Contact Dermatitis
  10.5.2 Atopic Dermatitis
  10.5.3 Psoriasis
  10.5.4 Urticaria
  10.5.5 Others
 10.6 Historic and Forecasted Market Size By Route Of Administration
  10.6.1 Oral
  10.6.2 Parenteral
  10.6.3 Topical
 10.7 Historic and Forecast Market Size by Country
  10.7.1 U.S.
  10.7.2 Canada
  10.7.3 Mexico

Chapter 11: Europe Pruritus Therapeutics Market Analysis, Insights and Forecast, 2016-2028
 11.1 Key Market Trends, Growth Factors and Opportunities
 11.2 Impact of Covid-19
 11.3 Key Players
 11.4 Key Market Trends, Growth Factors and Opportunities
 11.4 Historic and Forecasted Market Size By Drug Class
  11.4.1 Calcineurin Inhibitors
  11.4.2 Corticosteroids
  11.4.3 Counterirritants
  11.4.4 Immunosuppressant
  11.4.5 Antihistamines
  11.4.6 Others
 11.5 Historic and Forecasted Market Size By Disease Type
  11.5.1 Allergic Contact Dermatitis
  11.5.2 Atopic Dermatitis
  11.5.3 Psoriasis
  11.5.4 Urticaria
  11.5.5 Others
 11.6 Historic and Forecasted Market Size By Route Of Administration
  11.6.1 Oral
  11.6.2 Parenteral
  11.6.3 Topical
 11.7 Historic and Forecast Market Size by Country
  11.7.1 Germany
  11.7.2 U.K.
  11.7.3 France
  11.7.4 Italy
  11.7.5 Russia
  11.7.6 Spain
  11.7.7 Rest of Europe

Chapter 12: Asia-Pacific Pruritus Therapeutics Market Analysis, Insights and Forecast, 2016-2028
 12.1 Key Market Trends, Growth Factors and Opportunities
 12.2 Impact of Covid-19
 12.3 Key Players
 12.4 Key Market Trends, Growth Factors and Opportunities
 12.4 Historic and Forecasted Market Size By Drug Class
  12.4.1 Calcineurin Inhibitors
  12.4.2 Corticosteroids
  12.4.3 Counterirritants
  12.4.4 Immunosuppressant
  12.4.5 Antihistamines
  12.4.6 Others
 12.5 Historic and Forecasted Market Size By Disease Type
  12.5.1 Allergic Contact Dermatitis
  12.5.2 Atopic Dermatitis
  12.5.3 Psoriasis
  12.5.4 Urticaria
  12.5.5 Others
 12.6 Historic and Forecasted Market Size By Route Of Administration
  12.6.1 Oral
  12.6.2 Parenteral
  12.6.3 Topical
 12.7 Historic and Forecast Market Size by Country
  12.7.1 China
  12.7.2 India
  12.7.3 Japan
  12.7.4 Singapore
  12.7.5 Australia
  12.7.6 New Zealand
  12.7.7 Rest of APAC

Chapter 13: Middle East & Africa Pruritus Therapeutics Market Analysis, Insights and Forecast, 2016-2028
 13.1 Key Market Trends, Growth Factors and Opportunities
 13.2 Impact of Covid-19
 13.3 Key Players
 13.4 Key Market Trends, Growth Factors and Opportunities
 13.4 Historic and Forecasted Market Size By Drug Class
  13.4.1 Calcineurin Inhibitors
  13.4.2 Corticosteroids
  13.4.3 Counterirritants
  13.4.4 Immunosuppressant
  13.4.5 Antihistamines
  13.4.6 Others
 13.5 Historic and Forecasted Market Size By Disease Type
  13.5.1 Allergic Contact Dermatitis
  13.5.2 Atopic Dermatitis
  13.5.3 Psoriasis
  13.5.4 Urticaria
  13.5.5 Others
 13.6 Historic and Forecasted Market Size By Route Of Administration
  13.6.1 Oral
  13.6.2 Parenteral
  13.6.3 Topical
 13.7 Historic and Forecast Market Size by Country
  13.7.1 Turkey
  13.7.2 Saudi Arabia
  13.7.3 Iran
  13.7.4 UAE
  13.7.5 Africa
  13.7.6 Rest of MEA

Chapter 14: South America Pruritus Therapeutics Market Analysis, Insights and Forecast, 2016-2028
 14.1 Key Market Trends, Growth Factors and Opportunities
 14.2 Impact of Covid-19
 14.3 Key Players
 14.4 Key Market Trends, Growth Factors and Opportunities
 14.4 Historic and Forecasted Market Size By Drug Class
  14.4.1 Calcineurin Inhibitors
  14.4.2 Corticosteroids
  14.4.3 Counterirritants
  14.4.4 Immunosuppressant
  14.4.5 Antihistamines
  14.4.6 Others
 14.5 Historic and Forecasted Market Size By Disease Type
  14.5.1 Allergic Contact Dermatitis
  14.5.2 Atopic Dermatitis
  14.5.3 Psoriasis
  14.5.4 Urticaria
  14.5.5 Others
 14.6 Historic and Forecasted Market Size By Route Of Administration
  14.6.1 Oral
  14.6.2 Parenteral
  14.6.3 Topical
 14.7 Historic and Forecast Market Size by Country
  14.7.1 Brazil
  14.7.2 Argentina
  14.7.3 Rest of SA

Chapter 15 Investment Analysis

Chapter 16 Analyst Viewpoint and Conclusion

LIST OF TABLES

TABLE 001. EXECUTIVE SUMMARY
TABLE 002. PRURITUS THERAPEUTICS MARKET BARGAINING POWER OF SUPPLIERS
TABLE 003. PRURITUS THERAPEUTICS MARKET BARGAINING POWER OF CUSTOMERS
TABLE 004. PRURITUS THERAPEUTICS MARKET COMPETITIVE RIVALRY
TABLE 005. PRURITUS THERAPEUTICS MARKET THREAT OF NEW ENTRANTS
TABLE 006. PRURITUS THERAPEUTICS MARKET THREAT OF SUBSTITUTES
TABLE 007. PRURITUS THERAPEUTICS MARKET BY DRUG CLASS
TABLE 008. CALCINEURIN INHIBITORS MARKET OVERVIEW (2016-2028)
TABLE 009. CORTICOSTEROIDS MARKET OVERVIEW (2016-2028)
TABLE 010. COUNTERIRRITANTS MARKET OVERVIEW (2016-2028)
TABLE 011. IMMUNOSUPPRESSANT MARKET OVERVIEW (2016-2028)
TABLE 012. ANTIHISTAMINES MARKET OVERVIEW (2016-2028)
TABLE 013. OTHERS MARKET OVERVIEW (2016-2028)
TABLE 014. PRURITUS THERAPEUTICS MARKET BY DISEASE TYPE
TABLE 015. ALLERGIC CONTACT DERMATITIS MARKET OVERVIEW (2016-2028)
TABLE 016. ATOPIC DERMATITIS MARKET OVERVIEW (2016-2028)
TABLE 017. PSORIASIS MARKET OVERVIEW (2016-2028)
TABLE 018. URTICARIA MARKET OVERVIEW (2016-2028)
TABLE 019. OTHERS MARKET OVERVIEW (2016-2028)
TABLE 020. PRURITUS THERAPEUTICS MARKET BY ROUTE OF ADMINISTRATION
TABLE 021. ORAL MARKET OVERVIEW (2016-2028)
TABLE 022. PARENTERAL MARKET OVERVIEW (2016-2028)
TABLE 023. TOPICAL MARKET OVERVIEW (2016-2028)
TABLE 024. NORTH AMERICA PRURITUS THERAPEUTICS MARKET, BY DRUG CLASS (2016-2028)
TABLE 025. NORTH AMERICA PRURITUS THERAPEUTICS MARKET, BY DISEASE TYPE (2016-2028)
TABLE 026. NORTH AMERICA PRURITUS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION (2016-2028)
TABLE 027. N PRURITUS THERAPEUTICS MARKET, BY COUNTRY (2016-2028)
TABLE 028. EUROPE PRURITUS THERAPEUTICS MARKET, BY DRUG CLASS (2016-2028)
TABLE 029. EUROPE PRURITUS THERAPEUTICS MARKET, BY DISEASE TYPE (2016-2028)
TABLE 030. EUROPE PRURITUS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION (2016-2028)
TABLE 031. PRURITUS THERAPEUTICS MARKET, BY COUNTRY (2016-2028)
TABLE 032. ASIA PACIFIC PRURITUS THERAPEUTICS MARKET, BY DRUG CLASS (2016-2028)
TABLE 033. ASIA PACIFIC PRURITUS THERAPEUTICS MARKET, BY DISEASE TYPE (2016-2028)
TABLE 034. ASIA PACIFIC PRURITUS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION (2016-2028)
TABLE 035. PRURITUS THERAPEUTICS MARKET, BY COUNTRY (2016-2028)
TABLE 036. MIDDLE EAST & AFRICA PRURITUS THERAPEUTICS MARKET, BY DRUG CLASS (2016-2028)
TABLE 037. MIDDLE EAST & AFRICA PRURITUS THERAPEUTICS MARKET, BY DISEASE TYPE (2016-2028)
TABLE 038. MIDDLE EAST & AFRICA PRURITUS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION (2016-2028)
TABLE 039. PRURITUS THERAPEUTICS MARKET, BY COUNTRY (2016-2028)
TABLE 040. SOUTH AMERICA PRURITUS THERAPEUTICS MARKET, BY DRUG CLASS (2016-2028)
TABLE 041. SOUTH AMERICA PRURITUS THERAPEUTICS MARKET, BY DISEASE TYPE (2016-2028)
TABLE 042. SOUTH AMERICA PRURITUS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION (2016-2028)
TABLE 043. PRURITUS THERAPEUTICS MARKET, BY COUNTRY (2016-2028)
TABLE 044. ABBVIE INC.: SNAPSHOT
TABLE 045. ABBVIE INC.: BUSINESS PERFORMANCE
TABLE 046. ABBVIE INC.: PRODUCT PORTFOLIO
TABLE 047. ABBVIE INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 047. SANOFI SA: SNAPSHOT
TABLE 048. SANOFI SA: BUSINESS PERFORMANCE
TABLE 049. SANOFI SA: PRODUCT PORTFOLIO
TABLE 050. SANOFI SA: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 050. GALDERMA LABORATORIES LP: SNAPSHOT
TABLE 051. GALDERMA LABORATORIES LP: BUSINESS PERFORMANCE
TABLE 052. GALDERMA LABORATORIES LP: PRODUCT PORTFOLIO
TABLE 053. GALDERMA LABORATORIES LP: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 053. EPI HEALTH LLC: SNAPSHOT
TABLE 054. EPI HEALTH LLC: BUSINESS PERFORMANCE
TABLE 055. EPI HEALTH LLC: PRODUCT PORTFOLIO
TABLE 056. EPI HEALTH LLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 056. CARA THERAPEUTICS: SNAPSHOT
TABLE 057. CARA THERAPEUTICS: BUSINESS PERFORMANCE
TABLE 058. CARA THERAPEUTICS: PRODUCT PORTFOLIO
TABLE 059. CARA THERAPEUTICS: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 059. ACTAVIS: SNAPSHOT
TABLE 060. ACTAVIS: BUSINESS PERFORMANCE
TABLE 061. ACTAVIS: PRODUCT PORTFOLIO
TABLE 062. ACTAVIS: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 062. TREVI THERAPEUTICS: SNAPSHOT
TABLE 063. TREVI THERAPEUTICS: BUSINESS PERFORMANCE
TABLE 064. TREVI THERAPEUTICS: PRODUCT PORTFOLIO
TABLE 065. TREVI THERAPEUTICS: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 065. NOVARTIS AG: SNAPSHOT
TABLE 066. NOVARTIS AG: BUSINESS PERFORMANCE
TABLE 067. NOVARTIS AG: PRODUCT PORTFOLIO
TABLE 068. NOVARTIS AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 068. PFIZER INC.: SNAPSHOT
TABLE 069. PFIZER INC.: BUSINESS PERFORMANCE
TABLE 070. PFIZER INC.: PRODUCT PORTFOLIO
TABLE 071. PFIZER INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 071. MERCK & CO INC.: SNAPSHOT
TABLE 072. MERCK & CO INC.: BUSINESS PERFORMANCE
TABLE 073. MERCK & CO INC.: PRODUCT PORTFOLIO
TABLE 074. MERCK & CO INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 074. SUN PHARMACEUTICAL: SNAPSHOT
TABLE 075. SUN PHARMACEUTICAL: BUSINESS PERFORMANCE
TABLE 076. SUN PHARMACEUTICAL: PRODUCT PORTFOLIO
TABLE 077. SUN PHARMACEUTICAL: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 077. GLAXOSMITHKLINE PLC: SNAPSHOT
TABLE 078. GLAXOSMITHKLINE PLC: BUSINESS PERFORMANCE
TABLE 079. GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO
TABLE 080. GLAXOSMITHKLINE PLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 080. GLENMARK PHARMACEUTICALS LTD.: SNAPSHOT
TABLE 081. GLENMARK PHARMACEUTICALS LTD.: BUSINESS PERFORMANCE
TABLE 082. GLENMARK PHARMACEUTICALS LTD.: PRODUCT PORTFOLIO
TABLE 083. GLENMARK PHARMACEUTICALS LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 083. ABBOTT LABORATORIES: SNAPSHOT
TABLE 084. ABBOTT LABORATORIES: BUSINESS PERFORMANCE
TABLE 085. ABBOTT LABORATORIES: PRODUCT PORTFOLIO
TABLE 086. ABBOTT LABORATORIES: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 086. OTHER MAJOR PLAYERS: SNAPSHOT
TABLE 087. OTHER MAJOR PLAYERS: BUSINESS PERFORMANCE
TABLE 088. OTHER MAJOR PLAYERS: PRODUCT PORTFOLIO
TABLE 089. OTHER MAJOR PLAYERS: KEY STRATEGIC MOVES AND DEVELOPMENTS

LIST OF FIGURES

FIGURE 001. YEARS CONSIDERED FOR ANALYSIS
FIGURE 002. SCOPE OF THE STUDY
FIGURE 003. PRURITUS THERAPEUTICS MARKET OVERVIEW BY REGIONS
FIGURE 004. PORTER'S FIVE FORCES ANALYSIS
FIGURE 005. BARGAINING POWER OF SUPPLIERS
FIGURE 006. COMPETITIVE RIVALRYFIGURE 007. THREAT OF NEW ENTRANTS
FIGURE 008. THREAT OF SUBSTITUTES
FIGURE 009. VALUE CHAIN ANALYSIS
FIGURE 010. PESTLE ANALYSIS
FIGURE 011. PRURITUS THERAPEUTICS MARKET OVERVIEW BY DRUG CLASS
FIGURE 012. CALCINEURIN INHIBITORS MARKET OVERVIEW (2016-2028)
FIGURE 013. CORTICOSTEROIDS MARKET OVERVIEW (2016-2028)
FIGURE 014. COUNTERIRRITANTS MARKET OVERVIEW (2016-2028)
FIGURE 015. IMMUNOSUPPRESSANT MARKET OVERVIEW (2016-2028)
FIGURE 016. ANTIHISTAMINES MARKET OVERVIEW (2016-2028)
FIGURE 017. OTHERS MARKET OVERVIEW (2016-2028)
FIGURE 018. PRURITUS THERAPEUTICS MARKET OVERVIEW BY DISEASE TYPE
FIGURE 019. ALLERGIC CONTACT DERMATITIS MARKET OVERVIEW (2016-2028)
FIGURE 020. ATOPIC DERMATITIS MARKET OVERVIEW (2016-2028)
FIGURE 021. PSORIASIS MARKET OVERVIEW (2016-2028)
FIGURE 022. URTICARIA MARKET OVERVIEW (2016-2028)
FIGURE 023. OTHERS MARKET OVERVIEW (2016-2028)
FIGURE 024. PRURITUS THERAPEUTICS MARKET OVERVIEW BY ROUTE OF ADMINISTRATION
FIGURE 025. ORAL MARKET OVERVIEW (2016-2028)
FIGURE 026. PARENTERAL MARKET OVERVIEW (2016-2028)
FIGURE 027. TOPICAL MARKET OVERVIEW (2016-2028)
FIGURE 028. NORTH AMERICA PRURITUS THERAPEUTICS MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 029. EUROPE PRURITUS THERAPEUTICS MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 030. ASIA PACIFIC PRURITUS THERAPEUTICS MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 031. MIDDLE EAST & AFRICA PRURITUS THERAPEUTICS MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 032. SOUTH AMERICA PRURITUS THERAPEUTICS MARKET OVERVIEW BY COUNTRY (2016-2028)